Poor knowledge management delays regulatory approval and, thus, market access. Here's the first in a series examining the complexity of knowledge management for CMC and across the value stream.
Pursuing Growth Strategies And Aggressive Advocacy
Review what the president and CEO of a clinical-stage genomic medicines company had to say about growth strategy and his progress in the pursuit of gene therapies to address inherited retinal diseases.
|Connect With Pharmaceutical Online: